专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20100113541A1 CRYSTAL FORMS OF 2-(3-FLUORO-4-HYDROXYPHENYL)-7-VINYL-1,3-BENZOXAZOL-5-OL 审中-公开
标题翻译： 2-（3-氟-4-羟基苯基）-7-乙烯基-1,3-苯并恶唑-5-OL的晶体形式
公开(公告)号：US20100113541A1
公开(公告)日：2010-05-06
申请号：US12642273
申请日：2009-12-18
申请人： Abdolsamad TADAYON , Silvio IERA , Hong WEN , Marc S. TESCONI , Mannching Sherry KU
发明人： Abdolsamad TADAYON , Silvio IERA , Hong WEN , Marc S. TESCONI , Mannching Sherry KU
IPC分类号： A61K31/423 , C07D263/56 , A61P25/28 , A61P1/00 , A61P35/00 , A61P19/02 , A61P15/02 , A61P13/02 , A61P11/06 , A61P3/10
CPC分类号： C07D263/57
摘要： The present invention is directed to monohydrate and anhydrate crystal forms of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol, an estrogenic receptor modulator useful in the treatment of, for example, diseases related to abnormal levels of estrogen.
摘要翻译：本发明涉及2-（3-氟-4-羟基苯基）-7-乙烯基-1,3-苯并恶唑-5-醇的一水合物和无水晶体形式，可用于例如治疗的雌激素受体调节剂，与异常水平的雌激素相关的疾病。

2. 发明申请

US20100113443A1 LIQUID FORMULATIONS OF PHOSPHOLIPASE ENZYME INHIBITORS 审中-公开
标题翻译：磷脂酶抑制剂的液体配方
公开(公告)号：US20100113443A1
公开(公告)日：2010-05-06
申请号：US12513071
申请日：2007-10-30
申请人： Mannching Sherry Ku , Frances Anne Donahue , Eugene Lee
发明人： Mannching Sherry Ku , Frances Anne Donahue , Eugene Lee
IPC分类号： A61K31/404 , A61K31/5377 , A61K31/496 , A61K31/4439 , A61K31/422 , A61K31/4709
CPC分类号： A61K31/404 , A61K9/4858 , A61K47/10 , A61K47/14 , A61K47/22 , A61K47/44
摘要： The present invention relates to liquid formulations of inhibitors of phospholipase enzymes, such as cytosolic PLA2, compositions containing the same and processes for manufacture thereof.
摘要翻译：本发明涉及磷脂酶抑制剂的液体制剂，例如细胞溶质PLA2，含有它们的组合物及其制备方法。

3. 发明申请

US20130022610A1 METHODS OF DECREASING GLYCOSYLATED HEMOGLOBIN IN PATIENTS WITH DYSLIPIDEMIA 有权
标题翻译：糖尿病患者糖皮质激素降低的方法
公开(公告)号：US20130022610A1
公开(公告)日：2013-01-24
申请号：US13553271
申请日：2012-07-19
申请人： Mannching Sherry Ku , Chih-Kuang Chen , Wei-Shu Lu , Chih-Ming Chen , I-Yin Lin
发明人： Mannching Sherry Ku , Chih-Kuang Chen , Wei-Shu Lu , Chih-Ming Chen , I-Yin Lin
IPC分类号： A61K31/235 , A61K31/426 , A61P3/10 , A61K38/28 , A61K31/455 , A61P7/00 , A61K39/395 , A61K38/26
CPC分类号： A61K31/235 , A61K38/1793 , A61K45/06 , Y10S514/866 , A61K2300/00
摘要： Methods for treating abnormal glycosylated hemoglobin (HbA1c) levels in a patient in need thereof, wherein the provided methods comprise administering to a patient in need a therapeutically effective amount of an Interleukin-1β modulator. Also, the invention provides compositions comprising at least one lipid modifying agent and an IL-1β modulator.
摘要翻译：在有需要的患者中治疗异常糖基化血红蛋白（HbA1c）水平的方法，其中所提供的方法包括向需要的患者施用治疗有效量的白细胞介素-1bib; 调制器。此外，本发明提供包含至少一种脂质改性剂和IL-1和bgr的组合物; 调制器。

4. 发明申请

US20120289545A1 Maleate Salts of (E)-N--4-(Dimethylamino)-2-Butenamide and Crystalline Forms Thereof 有权
标题翻译：（E）-N-4-（二甲基氨基）-2-丁烯酰胺的马来酸盐及其结晶形式
公开(公告)号：US20120289545A1
公开(公告)日：2012-11-15
申请号：US13441168
申请日：2012-04-06
申请人： Qinghong Lu , Mannching Sherry Ku , Warren Chew , Gloria Cheal , Anthony F. Hadfield , Mahmoud Mirmehrabi
发明人： Qinghong Lu , Mannching Sherry Ku , Warren Chew , Gloria Cheal , Anthony F. Hadfield , Mahmoud Mirmehrabi
IPC分类号： A61K31/4709 , C07D401/14 , A61P35/00 , C07D401/12
CPC分类号： C07D401/12 , A61K31/4709 , C07C51/412 , C07C57/145
摘要： The present invention relates to maleate salt forms of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide, methods of preparing crystalline maleate salt forms, the associated compounds, and pharmaceutical compositions containing the same. The maleate salts are useful in treating cancers, particularly those affected by kinases of the epidermal growth factor receptor family.
摘要翻译：本发明涉及（E）-N- {4- [3-氯-4-（2-吡啶基甲氧基）苯胺基] -3-氰基-7-乙氧基-6-喹啉基} -4-（二甲基氨基）-2-丁烯酰胺，制备结晶马来酸盐形式的方法，相关化合物和含有它们的药物组合物。马来酸盐可用于治疗癌症，特别是受表皮生长因子受体家族激酶影响的癌症。

5. 发明授权

US08114869B2 Polymorph form II of tanaproget 失效
标题翻译： tanaproget的多晶型II
公开(公告)号：US08114869B2
公开(公告)日：2012-02-14
申请号：US13106494
申请日：2011-05-12
申请人： Marc Sadler Tesconi , Mannching Sherry Ku , Yan Xu
发明人： Marc Sadler Tesconi , Mannching Sherry Ku , Yan Xu
IPC分类号： A61K31/536 , A61P15/18 , C07D265/18
CPC分类号： C07D413/04 , C07D265/18 , C07B2200/13
摘要： Tanaproget polymorph Form II, processes for preparing tanaproget polymorph Form II, pharmaceutical compositions including tanaproget polymorph Form II, micronized tanaproget polymorph Form II, and processes for converting Form II to tanaproget Form I are provided. Also provided are methods of contraception, hormone replacement therapy, stimulation of food intake and treating or preventing uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, or carcinomas and adenocarcinomas comprising administering polymorph Form II to a mammalian subject.
摘要翻译： Tanaproget多晶型物II，制备tanaproget多晶型II的方法，包括tanaproget多晶型II，微粉化tanaproget多晶型II的药物组合物，以及将II型转化成tanaproget形式I的方法。还提供了避孕，激素替代疗法，刺激食物摄取和治疗或预防子宫肌层肌瘤，良性前列腺肥大，良性和恶性肿瘤性疾病，功能障碍性出血，子宫平滑肌瘤，子宫内膜异位症，多囊卵巢综合征或癌和腺癌的方法，包括向哺乳动物受试者施用多晶型II。

6. 发明申请

US20110212953A1 Polymorph Form II of Tanaproget 失效
标题翻译： Tanaproget的多晶型II型
公开(公告)号：US20110212953A1
公开(公告)日：2011-09-01
申请号：US13106494
申请日：2011-05-12
申请人： Marc Sadler Tesconi , Mannching Sherry Ku , Yan Xu
发明人： Marc Sadler Tesconi , Mannching Sherry Ku , Yan Xu
IPC分类号： A61K31/536 , C07D413/04 , A61P15/18 , A61P5/00 , A61P3/00 , A61P35/00 , A61P7/00 , A61P15/00
CPC分类号： C07D413/04 , C07D265/18 , C07B2200/13
摘要： Tanaproget polymorph Form II, processes for preparing tanaproget polymorph Form II, pharmaceutical compositions including tanaproget polymorph Form II, micronized tanaproget polymorph Form II, and processes for converting Form II to tanaproget Form I are provided. Also provided are methods of contraception, hormone replacement therapy, stimulation of food intake and treating or preventing uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, or carcinomas and adenocarcinomas comprising administering polymorph Form II to a mammalian subject.
摘要翻译： Tanaproget多晶型物II，制备tanaproget多晶型II的方法，包括tanaproget多晶型II，微粉化tanaproget多晶型II的药物组合物，以及将II型转化成tanaproget形式I的方法。还提供了避孕，激素替代疗法，刺激食物摄取和治疗或预防子宫肌层肌瘤，良性前列腺肥大，良性和恶性肿瘤性疾病，功能障碍性出血，子宫平滑肌瘤，子宫内膜异位症，多囊卵巢综合征或癌和腺癌的方法，包括向哺乳动物受试者施用多晶型II。

7. 发明授权

US07968709B2 Process for preparing polymorph form II of tanaproget 有权
标题翻译：制备tanaproget多晶型II的方法
公开(公告)号：US07968709B2
公开(公告)日：2011-06-28
申请号：US12792978
申请日：2010-06-03
申请人： Marc Sadler Tesconi , Mannching Sherry Ku , Yan Xu
发明人： Marc Sadler Tesconi , Mannching Sherry Ku , Yan Xu
IPC分类号： C07D265/18
CPC分类号： C07D413/04 , C07D265/18 , C07B2200/13
摘要： Tanaproget polymorph Form II, processes for preparing tanaproget polymorph Form II, pharmaceutical compositions including tanaproget polymorph Form II, micronized tanaproget polymorph Form II, and processes for converting Form II to tanaproget Form I are provided. Also provided are methods of contraception, hormone replacement therapy, stimulation of food intake and treating or preventing uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, or carcinomas and adenocarcinomas comprising administering polymorph Form II to a mammalian subject.
摘要翻译： Tanaproget多晶型物II，制备tanaproget多晶型II的方法，包括tanaproget多晶型II，微粉化tanaproget多晶型II的药物组合物，以及将II型转化成tanaproget形式I的方法。还提供了避孕，激素替代疗法，刺激食物摄取和治疗或预防子宫肌层肌瘤，良性前列腺肥大，良性和恶性肿瘤性疾病，功能障碍性出血，子宫平滑肌瘤，子宫内膜异位症，多囊卵巢综合征或癌和腺癌的方法，包括向哺乳动物受试者施用多晶型II。

8. 发明授权

US07759341B2 Polymorph form II of tanaproget 失效
标题翻译： tanaproget的多晶型II
公开(公告)号：US07759341B2
公开(公告)日：2010-07-20
申请号：US11412015
申请日：2006-04-26
申请人： Marc Sadler Tesconi , Mannching Sherry Ku , Yan Xu
发明人： Marc Sadler Tesconi , Mannching Sherry Ku , Yan Xu
IPC分类号： A61K31/536
CPC分类号： C07D413/04 , C07D265/18 , C07B2200/13
摘要： Tanaproget polymorph Form II, processes for preparing tanaproget polymorph Form II, pharmaceutical compositions including tanaproget polymorph Form II, micronized tanaproget polymorph Form II, and processes for converting Form II to tanaproget Form I are provided. Also provided are methods of contraception, hormone replacement therapy, stimulation of food intake and treating or preventing uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, or carcinomas and adenocarcinomas comprising administering polymorph Form II to a mammalian subject.
摘要翻译： Tanaproget多晶型物II，制备tanaproget多晶型II的方法，包括tanaproget多晶型II，微粉化tanaproget多晶型II的药物组合物，以及将II型转化成tanaproget形式I的方法。还提供了避孕，激素替代疗法，刺激食物摄取和治疗或预防子宫肌层肌瘤，良性前列腺肥大，良性和恶性肿瘤性疾病，功能障碍性出血，子宫平滑肌瘤，子宫内膜异位症，多囊卵巢综合征或癌和腺癌的方法，包括向哺乳动物受试者施用多晶型II。

9. 发明授权

US07419982B2 Crystalline forms of 5-chloro-6-{2,6-difluoro-4-[3-(methylamino)propoxy]phenyl}-N-[(1S)-2,2,2-trifluoro-1-methylethyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine salts 失效
标题翻译：结晶形式的5-氯-6- {2,6-二氟-4- [3-（甲基氨基）丙氧基]苯基} -N - [（1S）-2,2,2-三氟-1-甲基乙基] [1 ，2,4]三唑并[1,5-a]嘧啶-7-胺盐
公开(公告)号：US07419982B2
公开(公告)日：2008-09-02
申请号：US11437291
申请日：2006-05-19
申请人： Fang Fang Qi , Mannching Sherry Ku , Yanzhong Wu , David M. Blum
发明人： Fang Fang Qi , Mannching Sherry Ku , Yanzhong Wu , David M. Blum
IPC分类号： A01N43/90 , A61K31/519 , C07D487/00
CPC分类号： C07D487/04
摘要： The present invention relates to crystalline forms of 5-chloro-6-{2,6-difluoro-4-[3-(methylamino)propoxy]phenyl}-N-[(1S)-2,2,2-trifluoro-1-methylethyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine salts; processes for the production thereof; pharmaceutical compositions thereof; and methods for inhibiting tumor growth therewith.
摘要翻译：本发明涉及5-氯-6- {2,6-二氟-4- [3-（甲基氨基）丙氧基]苯基} -N - [（1S）-2,2,2-三氟-1- - 甲基乙基] [1,2,4]三唑并[1,5-a]嘧啶-7-胺盐; 生产过程; 其药物组合物; 以及抑制肿瘤生长的方法。

10. 发明申请

US20080199518A1 Controlled-release formulation of piperazine-piperidine antagonists and agonists of the 5-HT1A receptor having enhanced intestinal dissolution 审中-公开
标题翻译： 5-HT1A受体的哌嗪 - 哌啶拮抗剂和激动剂的控制释放制剂具有增强的肠溶解
公开(公告)号：US20080199518A1
公开(公告)日：2008-08-21
申请号：US11986991
申请日：2007-11-27
申请人： Mannching Sherry Ku , Wendy Ann Dulin , Yanning Lin
发明人： Mannching Sherry Ku , Wendy Ann Dulin , Yanning Lin
IPC分类号： A61K9/52 , A61K9/14 , A61K31/496 , A61P25/00 , A61K9/26
CPC分类号： A61K9/5078 , A61K9/1676 , A61K9/5026 , A61K9/5047
摘要： The present invention relates to controlled-release beads comprising diquinoline-substituted piperazine-piperidine compounds, such as 5-fluoro-8-{4-[4-[(6-methoxyquinolin-8-yl)piperazin-1-yl]piperidin-1-yl}quinoline, or pharmaceutically acceptable salts thereof; to multiple particulate formulations comprising such beads; to methods of preparing such beads; and to methods of treating 5-HT1A-related disorders using such beads and/or multiple particulate formulations.
摘要翻译：本发明涉及包含二喹啉取代的哌嗪 - 哌啶化合物的控释珠，例如5-氟-8- {4- [4 - [（6-甲氧基喹啉-8-基）哌嗪-1-基] 吡啶-1-基}喹啉或其药学上可接受的盐; 涉及包含这种珠粒的多种颗粒制剂; 制备这种珠粒的方法; 以及使用这种珠和/或多种颗粒制剂治疗5-HT 1A相关病症的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式